We have a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. Pimavanserin is also in Phase II development for Alzheimer's disease psychosis and has completed a Phase II trial as a co-therapy in schizophrenia. Our pipeline also includes clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two preclinical programs directed at Parkinson's disease and other neurological disorders. Our product candidates address diseases that are not well served by currently available therapies and represent large potential commercial market opportunities. We believe that our product candidates offer innovative therapeutic approaches and may provide significant advantages relative to current therapies.
Please click on the sub-links to this page to learn more about our product candidates and the targeted disease areas.back to top